| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
| 06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 192 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Evercore ISI starts OnKure stock with Outperform rating | 2 | Investing.com | ||
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 298 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 293 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,325 | +0,12 % | Warum dieser Strukturwandel in der Medizin Novo Nordisk, PanGenomic Health und Pfizer zu Must-Haves macht | Die Medizin von morgen denkt nicht in Krankheiten, sondern in Chancen. Ein radikaler Wandel von der Reparatur zur vorausschauenden Prävention revolutioniert den Gesundheitssektor und eröffnet massive... ► Artikel lesen | |
| SANOFI | 88,72 | +0,15 % | JPMORGAN stuft SANOFI auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi mit einem Kursziel von 105 Euro auf "Overweight" belassen. Analyst Richard Vosser wertet die Erkenntnisse aus der ElevAATe-Studie... ► Artikel lesen | |
| INNOCAN PHARMA | 9,850 | -1,50 % | InnoCan Pharma: Wie das "Wunder" funktioniert! | ||
| ASSEMBLY BIOSCIENCES | 25,000 | -0,40 % | Assembly Biosciences nach +279% in 6 Monaten: Was ist noch drin? | Mein Top-Favorit 2025 hat mit beeindruckender Stärke ein neues Langzeithoch markiert: Aktien von Assembly Biosciences kosten mittlerweile fast 30 US$, nachdem sie im April noch für 7,75 US$ zu haben... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 51,50 | -0,96 % | Nektar Therapeutics: Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting | SAN FRANCISCO, Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin... ► Artikel lesen | |
| JAGUAR HEALTH | 2,030 | +2,01 % | Jaguar Health, Inc.: Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600... ► Artikel lesen | |
| UNITED THERAPEUTICS | 364,50 | +1,22 % | If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today | ||
| ROYALTY PHARMA | 31,990 | -0,16 % | Dividende und Wachstum? Das geht! Mit RE Royalties, Royalty Pharma oder Evonik | An der Börse geht es nicht nur um Kurssteigerungen, auch Dividenden sind ziemlich attraktiv. Es gibt sogar professionelle Anlegergruppen, die sich fast ausschließlich auf kontinuierliche Erträge fokussieren.... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 46,170 | -1,05 % | BridgeBio Pharma, Inc.: BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week | ||
| CORBUS PHARMACEUTICALS | 15,200 | +4,83 % | Piper Sandler raises Corbus Pharmaceuticals stock price target on promising cancer drug data | ||
| SOLIGENIX | 1,605 | -0,31 % | SOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:... ► Artikel lesen | |
| KALA BIO | 0,675 | -2,46 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
| NEUROGENE | 24,160 | -6,14 % | Neurogene Inc. - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 1,884 | +2,14 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress | - Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,370 | +0,84 % | VYNE Therapeutics Inc.: VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo | Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from... ► Artikel lesen |